UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$498M |
| 2 |
Ametek
AME
|
+$445M |
| 3 |
Microsoft
MSFT
|
+$432M |
| 4 |
Apple
AAPL
|
+$209M |
| 5 |
Tesla
TSLA
|
+$198M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$759M |
| 2 |
Accenture
ACN
|
+$529M |
| 3 |
ConocoPhillips
COP
|
+$392M |
| 4 |
iShares Core S&P Total US Stock Market ETF
ITOT
|
+$324M |
| 5 |
iShares Core S&P Small-Cap ETF
IJR
|
+$310M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.01% |
| 2 | Healthcare | 15.34% |
| 3 | Financials | 12.73% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Industrials | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2176
Kinetik
KNTK
$7.98B
| $437K | ﹤0.01% |
13,200
| – | – |
|
2177
Corsair Gaming
CRSR
$1.55B
| $436K | ﹤0.01% |
32,159
| – | – |
|
|
INBX
2178
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $435K | ﹤0.01% |
+17,638
| New | +$518K |
|
2179
Atea Pharmaceuticals
AVIR
$420M
| $433K | ﹤0.01% |
90,068
+2,620
| +3% | +$13.3K |
|
2180
PetMed Express
PETS
$42.3M
| $427K | ﹤0.01% |
24,146
| – | – |
|
|
VMEO
2181
DELISTED
Vimeo
VMEO
| $427K | ﹤0.01% |
124,470
+19,935
| +19% | +$77.1K |
|
2182
Veru
VERU
$37.4M
| $426K | ﹤0.01% |
8,075
+738
| +10% | +$60.8K |
|
2183
Microvision
MVIS
$78.9M
| $426K | ﹤0.01% |
12,091
| – | – |
|
2184
Fluence Energy
FLNC
$2.44B
| $425K | ﹤0.01% |
+24,800
| New | +$391K |
|
|
ACLX
2185
DELISTED
Arcellx
ACLX
| $424K | ﹤0.01% |
+13,700
| New | +$314K |
|
2186
IonQ
IONQ
$16.6B
| $424K | ﹤0.01% |
123,014
| – | – |
|
2187
Senseonics Holdings Inc
SENS
$366M
| $424K | ﹤0.01% |
20,567
| – | – |
|
|
SGMO
2188
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $419K | ﹤0.01% |
133,554
| – | – |
|
2189
Evolus
EOLS
$501M
| $418K | ﹤0.01% |
55,661
+20,151
| +57% | +$156K |
|
2190
Kimbell Royalty Partners
KRP
$1.48B
| $418K | ﹤0.01% |
+25,020
| New | +$440K |
|
2191
nLIGHT
LASR
$3.17B
| $418K | ﹤0.01% |
41,192
| – | – |
|
2192
Opko Health
OPK
$1.02B
| $418K | ﹤0.01% |
334,071
| – | – |
|
|
VERV
2193
DELISTED
Verve Therapeutics
VERV
| $413K | ﹤0.01% |
21,355
-6,147
| -22% | -$163K |
|
|
ITOS
2194
DELISTED
iTeos Therapeutics
ITOS
| $413K | ﹤0.01% |
+21,137
| New | +$413K |
|
2195
Dr. Reddy's Laboratories
RDY
$10.2B
| $411K | ﹤0.01% |
39,735
| – | – |
|
2196
Alkami Technology
ALKT
$2.11B
| $409K | ﹤0.01% |
28,026
| – | – |
|
|
REVG
2197
DELISTED
REV Group
REVG
| $407K | ﹤0.01% |
32,254
-301
| -0.9% | -$3.96K |
|
|
MMAT
2198
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $406K | ﹤0.01% |
3,415
-2,021
| -37% | -$267K |
|
2199
Codexis
CDXS
$158M
| $406K | ﹤0.01% |
87,084
+8,144
| +10% | +$44.6K |
|
|
TPC
2200
Tutor Perini Cor
TPC
$5.21B
| $406K | ﹤0.01% |
53,744
| – | – |
|
Similar funds
UBS AM's Q4 2022 Portfolio in Review
As of Q4 2022, UBS AM held 2,824 positions worth $191B, up 7% from $178B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
UBS AM's Q4 2022 filing shows 88 new, 1,334 increased, 722 reduced and 301 closed positions. Its largest new stake was Ferguson: 543,379 shares worth $69M. The largest sale was Amgen, an estimated $759M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q4 2022 buy was Ferguson: 543,379 shares worth $69M.
- UBS AM added most to Amazon in Q4 2022, an estimated $498M increase.
- UBS AM's biggest Q4 2022 reduction was Accenture, cutting an estimated $529M.
- UBS AM fully exited Amgen in Q4 2022, selling an estimated $759M.
- UBS AM's ten largest holdings make up 19% of its $191B portfolio in Q4 2022.
- UBS AM opened 88 new positions and closed 301 in Q4 2022.
- UBS AM's portfolio value rose 7% quarter-over-quarter to $191B.
Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.